Kevin Andrews, Ph.D.
Licensing, product acquisition, contract research, proof of concept leading to scale-up to manufacturing, joint development, supplier agreement
An opportunity to participate in a portion of a $2 billion annual market
Phase 1 – Proof of concept in 6-9 months
Phase 2 – Engineering development in 6-18 months
Phase 1 – Funding is available to support efforts to make samples for sponsor evaluation
SOLUTION PROVIDER HELP DESK:
NineSigma, representing a global health care products company, invites proposals for technology or processes to enhance or control silver solubility in aqueous systems.
NineSigma’s client manufactures wound dressings in which they incorporate silver as an antimicrobial agent. The client incorporates silver by adding aqueous silver sulfate to hydrophilic polymer media precursors as they make a foam substrate. As a result, silver particles become embedded in the foam. When the wound dressing is placed over a wound, the dressing pulls fluids from the wound by capillary action. Some of the silver in the dressing becomes solvated during the process, delivering silver as an antimicrobial agent to inhibit infection.
NineSigma’s client is interested in three scenarios for silver solubility: i) product manufacture, ii) initial use of wound dressing, and iii) ongoing use of wound dressing. Each of these scenarios has slightly different requirements for controlling silver solubility.
Ideally, it would be useful for silver solubility to be rapid and complete, to permit the rapid uptake of silver into the foam matrix. It may also be useful to control the rate of uptake to match the kinetics of the foam formation.
Just after application of a wound dressing, at short time scales, the quantity of fluid available to solvate silver may be small, leading to small concentration gradients between the dressing and the wound. There is also a need for faster silver ion deployment to prevent (or begin to eliminate) microbial growth.
As time elapses, with a wound dressing in place, it is important to manage the release of silver ions to maintain antimicrobial performance without releasing too much silver.
NineSigma’s client is interested in technology or processes to control silver solubility in one or more of these scenarios.
The successful technology will:
Anticipated Project Phases or Project Plan
Phase 1 – Proof of concept
Phase 2 – Engineering development
Criteria for Moving from Phase 1 to Phase 2
Client will consider for advancement an approach that meets performance criteria with acceptable economics and pathway to commercialization.
Possible approaches might include, but are not limited to:
Your response should address the following:
Appropriate responses to this Request
Responses from companies (small to large), consultants, venture capitalists, entrepreneurs, or inventors are welcome.
You represent a company or university that has demonstrated a proof of concept.
You represent a company or university that has reduced method to practice at lab scale.
You represent a company or university that has developed a method for use at pilot scale.
You represent a company or university that has demonstrated a method ready for implementation at industrial scale.
You represent a university research department that has a bench-scale demonstration ready to adapt.
You represent a university research department that has an undeveloped pathway with a high probability of success.